A Phase 4 interventional study of opt out enrollment, tailored counseling, varenicline started prior to target quit date and opt in enrollment, non-tailored counseling, varenicline started prior to target quit date in Tobacco Use, Tobacco Smoking and Tobacco Use Cessation, sponsored by Albert Einstein College of Medicine. Completed at 1 site in United States. Open to participants aged 40 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-05.
Sponsored by Albert Einstein College of Medicine · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 186 studies in Tobacco Smoking with a site in United States — 24 open to participants now, 30 under way, 2 of them phase 3. Tobacco Smoking · United States.
Among the 186 studies in Tobacco Smoking with a site in United States, this one is the 151st largest by enrollment of the 178 interventional ones that give a count, is one of 12 that started in 2024, is one of 10 in phase 4, and was the 164th registered.
265 studies on the registry are indexed under Tobacco Smoking; 43 are open to participants now.
Browse Tobacco Smoking studies →24 of the 186 studies in Tobacco Smoking with a site in United States are open now. Recruiting first, the newest first:
RAI Services Company · Sites in United States
Ages 21–65 · Healthy volunteers
RAI Services Company · Sites in United States
Ages 21–65 · Healthy volunteers
Binghamton University · Sites in United States
Ages 18+
RAI Services Company · Sites in United States
Ages 21–65 · Healthy volunteers
RAI Services Company · Sites in United States
Ages 21–65 · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 34 Tobacco Smoking studies recruiting now, 15 (44%) set no upper age limit and 17 (50%) stop at 75 or younger; 2 take children under 18; 17 take healthy volunteers.
This study: 40 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
186 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 11 · Phase 3 5 · Phase 4 10
First in 2001; this study’s year is marked. 12 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 23 is below the median of 120 across 230 interventional studies indexed under Tobacco Smoking.
Median enrollment 111 across the 178 interventional studies, 627 across the 8 observational. Of the 147 that completed or were terminated, 65 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
44 of 186 have an industry lead sponsor. The 10 most frequent:
Albert Einstein College of Medicine is the lead sponsor of 201 studies on the registry; 21 are open to participants now.
Of its 46 completed or terminated interventional studies of FDA-regulated products, 37 (80%) have results posted.
Albert Einstein College of Medicine has 1 study filed under Tobacco Smoking — fewer than ten, so there is no comparison to draw.
16 of the studies in Tobacco Smoking with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03442413University of PennsylvaniaNicotinic Hepatic Metabolism on Neuroreceptor Substrates of Nicotine Addiction | 2026-11-22 |
| NCT06945120Dana-Farber Cancer InstituteACT Lung Health Intervention: Phase Two | 2026-11-30 |
| NCT07710820RAI Services CompanyA Multi-Site Study to Assess the Effect of Availability of a Heated Tobacco Product on Smoking Abstinence Among Current Primary Cigarette Smokers | 2026-12 |
| NCT05445804Johns Hopkins UniversityOral Cannabidiol for Tobacco Cessation | 2026-12-01 |
| NCT07598136RAI Services CompanyA Study to Determine the Effects of ENDS Flavor Availability on Abstinence Within Smokers | 2026-12-17 |
Add all 16 to your calendar (.ics) → With an account.
Among the 186 studies in Tobacco Smoking with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
At the Fire Department of the City of New York (FDNY) World Trade Center Health Program, 36% of participants in the low dose computed tomography (LDCT) lung cancer screening program are current smokers, despite referral to the free FDNY Tobacco Cessation Program (Standard Care). Investigators propose testing an Enhanced Care program which includes opt-out enrollment; tobacco cessation counseling will be individually tailored to spirometry/LDCT results and treatment with varenicline starting 4 weeks prior to their target quit date. This randomized trial will compare enrollment and cessation outcomes in Standard Care vs. Enhanced Care groups of challenging-to-treat, high-risk smokers.
The overarching goal of this Randomized Controlled trial is to develop and test an effective, scalable intervention with potential to reach high-risk smokers undergoing CT lung cancer screening who have not engaged in or succeeded with traditional tobacco treatment approaches. The investigators will test an Enhanced Care intervention specifically designed to address multiple challenges to tobacco treatment engagement and success. First, the researchers will test opt-out enrollment in cessation treatment. The current tobacco treatment default, in which patients must opt-in to cessation treatment and are only offered counseling and pharmacotherapy when deemed ready to quit, results in missed opportunities to engage smokers into treatment. Previous studies of opt-out enrollment in cessation treatment suggest that an opt-out tobacco treatment strategy substantially increases engagement and cessation rates compared with traditional opt-in approaches. Second, proactive counseling will leverage the "reachable, teachable moment" of CT screening to motivate cessation through individually tailored messaging tied to CT results and lung function spirometry. Using CT results as a motivational tool has shown promise in pilot studies. The optimal approach and success of using CT coupled with spirometry results to motivate tobacco cessation remains unknown. Third, investigators will offer varenicline pre-loading to all enrollees, regardless of study arm, in which varenicline is initiated 4 weeks prior to target quit date. This approach is associated with decreased pre-quit tobacco-associated reward and double the rate of abstinence compared with standard varenicline treatment.
The investigators thus propose a randomized trial among retired FDNY World Trade Center Health Program responders eligible for the FDNY World Trade Center Health Program CT screening program to test the effects of Enhanced Care (opt-out enrollment, tailored counseling based on CT and spirometry results, and varenicline with preloading) against Standard Care (opt-in enrollment, standard cessation counseling without spirometry/CT tailoring, and varenicline with preloading) in the engagement of high-risk smokers in cessation treatment and the achievement of tobacco abstinence.
265 studies on the registry are indexed under Tobacco Smoking; 43 are open to participants now.
This study's enrollment of 23 is below the median of 120 across 230 interventional studies indexed under Tobacco Smoking.
Browse Tobacco Smoking studies →Albert Einstein College of Medicine is the lead sponsor of 201 studies on the registry; 21 are open to participants now.
Of its 46 completed or terminated interventional studies of FDA-regulated products, 37 (80%) have results posted.
Compared within Tobacco Smoking, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Tobacco Use. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Opt-out counseling enrollment. individually-tailored biofeedback linked to Chest CT and spirometry results. Varenicline: Preloading regimen (prior to target quit date): 0.5 mg once a day for days 1-3, 0.5 mg twice a day for days 4-7, and 1 mg twice a day for days 8-28. 1 mg twice day for 12 weeks after target quit date.
Other: opt out enrollment, tailored counseling, varenicline started prior to target quit date
Opt-in counseling enrollment. Standard tobacco cessation counseling. Varenicline: Preloading regimen (prior to target quit date): 0.5 mg once a day for days 1-3, 0.5 mg twice a day for days 4-7, and 1 mg twice a day for days 8-28. 1 mg twice day for 12 weeks after target quit date.
Other: opt in enrollment, non-tailored counseling, varenicline started prior to target quit date
Participants automatically enrolled in motivational counseling. Tailored counseling includes sharing results of Chest CT results and lung function spirometry tests with participants.
Participants must opt-in to receive counseling. Counseling does not include discussion of Chest CT or spirometry results.
Enrollment
Enrollment is defined as all participants who completed at least one session with our tobacco treatment specialist in FDNY's Tobacco Cessation Program: Standard vs. Enhanced Care arms. The number of participants who attend at least one study visit with the tobacco treatment specialist from the eligible recruitment population will be tabulated and reported.
Time frame: Baseline (Week 0)
Number of Participants With (Biochemically Validated) Tobacco Abstinence
7-day point prevalence abstinence will be biochemically verified by the analysis of urine samples collected at a laboratory nearest each participant's residence. Urine sample collection will occur at weeks 2, 4, 8, 12, and 16 along with a 12-week post end of treatment (EOT) timepoint at 28 weeks. Samples will be analyzed for urine cotinine which is the commonly measured biomarker of nicotine intake. Urine cotinine levels \< 20 ng/mL will be used to verify tobacco abstinence. Data will be summarized at each timepoint by study arm from weeks 2 - weeks 28 using basic descriptive statistics at each research assessment visit.
Time frame: Weeks 2, 4, 8, 12, and 16 along with a 12-week post end of treatment (EOT) timepoint visit at 28 weeks
Retention to Study End-Date
Retention will be assessed and reported as the number of participants retained in the study through the time of the 12-week post end of treatment (EOT) timepoint at 28 weeks.
Time frame: Through the 12-week post EOT timepoint at 28 weeks
Number of Participants Who Attended Counseling Visit at Each Timepoint - Counseling Adherence
Counseling adherence will be determined by the number of counseling visits attended. Tobacco counseling sessions will occur at baseline, and at weeks 2, 4, 8, 12, and 16 along with a 12-week post end of treatment (EOT) timepoint at 28 weeks. Counseling adherence will be summarized by study arm based on attendance during each individual session (timepoint) and reported as a continuous variable for each timepoint (counseling visit).
Time frame: Baseline, Weeks 2, 4, 8, 12, 16, and the 12-week post EOT timepoint visit at 28 weeks
Pill Count Percentage - Varenicline Adherence
Varenicline adherence will be measured using pill count percentage, recorded as the number of pills taken divided by the number of pills prescribed, per participant, corresponding to the dosing regimen. Varenicline adherence data will be summarized by study arm using basic descriptive statistics for each week of treatment. Participants refusing medication will be counted as zero. Participants discontinuing medication due to reported side effects or adverse events will be excluded from calculation totals. Medication adherence rates in excess of 100% (e.g., subjects mistakenly took extra pills) will be reported as 100% adherence. Similarly, medication adherence rates below zero (e.g., subjects added pills to the bottle but did not remove any pills) will be reported as 0% adherence. Pill count adherence is an objective measure that has been shown to correlate with electronic monitors and varenicline plasma levels.
Time frame: Baseline, Weeks 2, 4, 8, 12, and 16
Randomization into Enhanced Care (EC) or Standard Care (SC) was completed prior to recruitment. Both treatment arms received a mailed recruitment letter. EC participants were instructed to contact the study coordinator if they wished to opt-out. SC participants received a mailed letter and were instructed to contact the coordinator if they wished to participate. The coordinator contacted EC participants to complete consent procedures and schedule visits. Recruitment procedures began in May 2024.
| Milestone | Enhanced Care | Standard Care |
|---|---|---|
| Started | 17 | 6 |
| Completed | 4 | 2 |
| Not completed | 13 | 4 |
| Withdrew: Lost to follow-up | 11 | 4 |
| Withdrew: Excluded | 2 | 0 |
Enrollment is defined as all participants who completed at least one session with our tobacco treatment specialist in FDNY's Tobacco Cessation Program: Standard vs. Enhanced Care arms. The number of participants who attend at least one study visit with the tobacco treatment specialist from the eligible recruitment population will be tabulated and reported.
| Participants | Enhanced Care | Standard Care |
|---|---|---|
| Enrollment | 12 | 5 |
7-day point prevalence abstinence will be biochemically verified by the analysis of urine samples collected at a laboratory nearest each participant's residence. Urine sample collection will occur at weeks 2, 4, 8, 12, and 16 along with a 12-week post end of treatment (EOT) timepoint at 28 weeks. Samples will be analyzed for urine cotinine which is the commonly measured biomarker of nicotine intake. Urine cotinine levels \< 20 ng/mL will be used to verify tobacco abstinence. Data will be summarized at each timepoint by study arm from weeks 2 - weeks 28 using basic descriptive statistics at each research assessment visit.
| Participants | Enhanced Care | Standard Care |
|---|---|---|
| Week 2 | 0 | 0 |
| Week 4 | 2 | 0 |
| Week 8 | 2 | 3 |
| Week 12 | 2 | 3 |
| Week 16 | 2 | 2 |
| Week 28 | 1 | 2 |
Retention will be assessed and reported as the number of participants retained in the study through the time of the 12-week post end of treatment (EOT) timepoint at 28 weeks.
| Participants | Enhanced Care | Standard Care |
|---|---|---|
| Retention to Study End-Date | 4 | 2 |
Counseling adherence will be determined by the number of counseling visits attended. Tobacco counseling sessions will occur at baseline, and at weeks 2, 4, 8, 12, and 16 along with a 12-week post end of treatment (EOT) timepoint at 28 weeks. Counseling adherence will be summarized by study arm based on attendance during each individual session (timepoint) and reported as a continuous variable for each timepoint (counseling visit).
| Participants | Enhanced Care | Standard Care |
|---|---|---|
| Baseline | 12 | 5 |
| Week 2 | 10 | 3 |
| Week 4 | 9 | 3 |
| Week 8 | 7 | 3 |
| Week 12 | 7 | 3 |
| Week 16 | 6 | 3 |
| Week 28 | 4 | 2 |
Varenicline adherence will be measured using pill count percentage, recorded as the number of pills taken divided by the number of pills prescribed, per participant, corresponding to the dosing regimen. Varenicline adherence data will be summarized by study arm using basic descriptive statistics for each week of treatment. Participants refusing medication will be counted as zero. Participants discontinuing medication due to reported side effects or adverse events will be excluded from calculation totals. Medication adherence rates in excess of 100% (e.g., subjects mistakenly took extra pills) will be reported as 100% adherence. Similarly, medication adherence rates below zero (e.g., subjects added pills to the bottle but did not remove any pills) will be reported as 0% adherence. Pill count adherence is an objective measure that has been shown to correlate with electronic monitors and varenicline plasma levels.
| Pill Count Percentage | Enhanced Care | Standard Care |
|---|---|---|
| Week 2 | 79.23 (0 to 100) | 92.06 (76.19 to 100) |
| Week 4 | 65.63 (0 to 100) | 66.67 (0 to 100) |
| Week 8 | 50.00 (0 to 100) | 64.54 (0 to 100) |
| Week 12 | 45.42 (0 to 100) | 59.89 (0 to 98.28) |
| Week 16 | 25.00 (0 to 75) | 37.36 (0 to 100) |
Enrollment - Informed Consent, defined as the number of participants who completed the study informed consent with the study coordinator indicating their intent to participate in the study, regardless of their attendance at the initial or subsequent study visitations. This quantity will be tabulated and reported as a percentage of the eligible recruitment populations by Standard vs. Enhanced Care arms. The time frame for this measure uses the completion date of the informed consent, prior to the Baseline (Week 0) study visit. Participants who completed informed consent but did not subsequently complete any study procedures were not followed or monitored and were recorded as lost to follow-up.
| Participants | Enhanced Care | Standard Care |
|---|---|---|
| Enrollment - Informed Consent | 17 | 6 |
7-day self-reported tobacco abstinence will be assessed using self-report survey data collect at baseline and at weeks 2, 4, 8, 12, and 16 along with a 12-week post end of treatment (EOT) timepoint at 28 weeks, where participants were asked either "Do you now currently smoke cigarettes" at baseline, and "In the time since your last study visit, have you smoked any cigarettes (even a puff)". Data will be summarized at each timepoint by study arm using data from each research assessment with basic descriptive statistics. This measure was added as a supplemental outcome, to describe cessation results where collection of biomarker nicotine metabolites were not completed.
| Participants | Enhanced Care | Standard Care |
|---|---|---|
| Baseline | 0 | 0 |
| Week 2 | 0 | 0 |
| Week 4 | 2 | 0 |
| Week 8 | 3 | 3 |
| Week 12 | 5 | 3 |
| Week 16 | 3 | 2 |
| Week 28 | 3 | 2 |
Number of participants who demonstrate a reduction in their average number of cigarettes smoked per day that is greater than or equal to at least 50% of the quantity of self-reported cigarettes smoked per day during their baseline survey. This single time point measure evaluates changes in smoking behavior. In the case of missing survey data, this measure was calculated using the most recent self-report survey data available, from weeks 2, 4, 8, 12, and 16 along with a 12-week post end of treatment (EOT) timepoint at 28 weeks. Counts are reported in units of number of participants, and are shown by study arm. During study analyses this outcome was added as a post-hoc outcome.
| Participants | Enhanced Care | Standard Care |
|---|---|---|
| Number of Participants Who Demonstrate Cigarette Use Reduction | 8 | 3 |
Collected over From enrollment until end of follow-up, up to 28 weeks.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Enhanced Care | 0/12 (0%) | 0/12 (0%) | 5/12 (41.7%) |
| Standard Care | 0/5 (0%) | 0/5 (0%) | 2/5 (40%) |
| Event | Enhanced Care | Standard Care |
|---|---|---|
| Sleep Disturbances/Abnormal DreamsGeneral disorders | 4/12 | 1/5 |
| NauseaGeneral disorders | 1/12 | 1/5 |
| Oral/DentalGeneral disorders | 1/12 | 1/5 |
| Joint PainMusculoskeletal and connective tissue disorders | 0/12 | 1/5 |
| HeadacheGeneral disorders | 1/12 | 0/5 |
Numbers reported in Baseline Characteristics includes all enrolled participants who completed the informed consent, regardless of their attendance at subsequent study visits.
| Age, Categorical(Participants) | Enhanced Care | Standard Care | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 11 | 3 | 14 |
| >=65 years | 6 | 3 | 9 |
| Age, Continuous(Years) | Enhanced Care | Standard Care | Total |
|---|---|---|---|
| Mean | 61.8 ± 5.0 | 64.5 ± 6.2 | 62.5 ± 5.3 |
| Sex: Female, Male(Participants) | Enhanced Care | Standard Care | Total |
|---|---|---|---|
| Female | 4 | 0 | 4 |
| Male | 13 | 6 | 19 |
| Ethnicity (NIH/OMB)(Participants) | Enhanced Care | Standard Care | Total |
|---|---|---|---|
| Hispanic or Latino | 1 | 0 | 1 |
| Not Hispanic or Latino | 16 | 6 | 22 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Enhanced Care | Standard Care | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 1 | 0 | 1 |
| White | 15 | 6 | 21 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 1 | 0 | 1 |
| Region of Enrollment(participants) | Enhanced Care | Standard Care | Total |
|---|---|---|---|
| United States | 17 | 6 | 23 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — The datasets generated and analyzed during the current study are not publicly available, but a deidentified dataset may be available from the principal investigator upon reasonable request.
Ran from May 2024 to primary completion in Oct 2025, 16 months.
Results were first posted in Nov 2026, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Albert Einstein College of Medicine →